Long-Term NSAID Use by Hypertensive Patients with Coronary Artery Disease Increases Risk of Adverse Events
According to New Study in The American Journal of Medicine
New York, NY, July 12, 2011 – A study published in the July issue of The American Journal of Medicine, reports that among hypertensive patients with coronary artery disease, chronic self-reported use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of adverse events during long-term follow-up. Long-term NSAID use is common for treatment of chronic pain.
Researchers from the Division of Cardiovascular Medicine, College of Medicine and the Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, found that after a mean of 2.7 years of follow-up, in hypertensive patients with coronary artery disease (average age of 65 years), chronic self-reported NSAID use was associated with a 47% increase in the occurrence of death, nonfatal myocardial infarction, or nonfatal stroke. This was due to a 90% increase in all-cause mortality (which persisted into extended follow-up of more than 5 years), a 126% increase in cardiovascular mortality, and a 66% increase in total myocardial infarctions. There was no significant difference in the occurrence of stroke.
"Among coronary artery disease patients with hypertension, chronic self-reported use of NSAIDs was associated with harmful outcomes, and this practice should be avoided where possible,” commented Anthony A. Bavry, MD, MPH, Assistant Professor, Division of Cardiovascular Medicine, College of Medicine at the University of Florida, Gainesville. “This association did not appear to be due to elevated blood pressure because chronic NSAID users actually had slightly lower on-treatment blood pressure over a mean of 2.7 years of follow-up. Until further data are available, alternative modes of pain relief should be considered for these patients."
Currently, there is a paucity of data about possible harmful effects of chronic NSAIDs in patients with hypertension and coronary artery disease. This observational study was conducted within a large randomized trial that provided long-term blood pressure measures, target blood pressures, and standardized assessment of adverse cardiovascular outcomes.
Data were obtained from INVEST (The INternational VErapamil Trandolapril Study), a randomized trial conducted in 14 countries, originally designed to compared the effects of a calcium antagonist (verapamil SR)-based strategy with a beta-blocker (atenolol)-based strategy for hypertension among patients with stable coronary artery disease. In this study, there were 882 chronic NSAID users and 21,694 nonchronic NSAID users. Many of the previous analyses on this topic have been conducted from case-control studies.
Interestingly investigators did not find a difference in serious gastrointestinal bleeding events from chronic NSAID use, as might have been expected. While this was somewhat counterintuitive, chronic NSAID users likely started these medications before study enrollment, at which time major bleeding events could have occurred.
The article is "Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease" by Anthony A. Bavry, MD, MPH, Asma Khaliq, MD, Yan Gong, PhD, Eileen M. Handberg, PhD, Rhonda M. Cooper-DeHoff, PharmD, MS, and Carl J. Pepine, MD. It appears in The American Journal of Medicine, Volume 124, Issue 7 (July 2011) published by Elsevier.
# # #
Notes For Editors
Full text of the article is available to credentialed journalists upon request. Contact Pamela Poppalardo at 732-238-3628 email@example.com to obtain copies. To schedule an interview with the authors please contact Juliann Whitebread, Department of Medicine, University of Florida, 352-265-8055, Juliann.Whitebread@medicine.ufl.edu.
About The American Journal of Medicine
The American Journal of Medicine ( http://www.amjmed.com), known as the “Green Journal,” is one of the oldest and most prestigious general internal medicine journals published in the United States. It has an Impact Factor of 5.115, which ranks it 14 out of 151 General and Internal Medicine titles according to the Journal Citation Reports® 2010 published by Thomson Reuters.
AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus U.S. medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com